Search Results

The Committee to Restore Nymox Shareholder Value, Inc., with a goal to recover shareholder value in Nymox Pharmaceutical Corporation, issued the following statement to Nymox shareholders regarding the special meeting of shareholders originally scheduled to be held on November 8, 2023, which it validly called in accordance with the Order of the Supreme Court, Commercial Division, of the Commonwealth of the Bahamas, filed October 5, 2023.

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.

The Committee to Restore Nymox Shareholder Value, LLC, with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP by reestablishing a proposed partnership with a highly respected, global specialty pharmacy and healthcare solutions company, resolutely refutes all allegations made in a press release by current Nymox leadership.

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] is pleased to announce the completion of its recently reported private placement of USD 2 million.

Nymox Pharmaceutical Corporation is pleased to provide a current update on the Company’s ongoing projects.

Nymox Pharmaceutical Corporation received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company’s shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023.

Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company’s recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been validated by the U.K. authorities, at U.K. Medicines & Healthcare products Regulatory Agency (MHRA).